R&D News | pharmaphorum

News

Which biotechs have raised new VC financing this week?

Our latest roundup of financings in the biotech sector includes solid eight-figure rounds for Triveni, Cellares, HMNC, Vedana, and Neion Bio.

News

Heart drug biotech Kardigan raises $400m in upscaled IPO

Cardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated.

News

RayThera founders Qing Dong and Gene Hung

Biogen pens $1bn deal to buy immunology biotech RayThera

Biogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion.

News

Jazz orchestrates a $4bn cancer alliance with AbCellera

Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.

News

MSD steps out with Protillion in $510m+ AI shindig

MSD has teamed up with Protillion Bio in a deal worth more than $510m, focusing on using the AI start-up's lab-in-the-loop platform for drug discovery

News

Jeremy Skillington, Poolbeg's chief executive

Poolbeg expects first data for CRS drug in the summer

A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.

Which biotechs have raised new VC financing this week?

Heart drug biotech Kardigan raises $400m in upscaled IPO

Biogen pens $1bn deal to buy immunology biotech RayThera

Jazz orchestrates a $4bn cancer alliance with AbCellera

MSD steps out with Protillion in $510m+ AI shindig

Poolbeg expects first data for CRS drug in the summer

PMV cues up filing for first p53-directed cancer therapy

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks